ClinicalTrials.gg
RecruitingNCT07073079CROHNOSUpdated Jun 24, 2026

A Study to Assess the Effectiveness of Second-Line Therapy of Upadacitinib and Risankizumab in Adult Participants With Crohn's Disease in a Real-World Setting

An observational study in Crohn's Disease, sponsored by AbbVie. Recruiting at 25 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-24.

Sponsored by AbbVie · Observational

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
250
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 55 studies in Crohn Disease by AbbVie — 6 open to participants now, 14 under way, 6 of them phase 3. Crohn Disease · AbbVie.

Planned enrollment
14th of 26
250 · median 252
Started
2025
the only one that year
Observational
26 of 55
3 open now
Primary completion
2027-12
later than 2 of 13 live
Registered
53rd of 55
by date

Among the 55 studies in Crohn Disease by AbbVie, this one is the 14th largest by planned enrollment of the 26 observational ones that give a count, is the only one that started in 2025, is one of 26 observational ones, reaches primary completion later than 2 of the 13 other live ones, and was the 53rd registered.

Crohn Disease

1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

6 of the 55 studies in Crohn Disease by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Crohn Disease by AbbVie, or all of them as a file.
02

Study summary

Crohn's disease (CD) is an incurable chronic inflammatory disorder of the gastrointestinal tract. This study will evaluate the second line effectiveness of upadacitinib and risankizumab in Crohn's Disease (CD) in a real-world setting.

Upadacitinib and risankizumab are approved drugs for treating CD. Approximately 250 participants who are prescribed upadacitinib or risankizumab by their physician in accordance with local label will be enrolled in 25 sites across Italy.

Participants will receive upadacitinib or risankizumab as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed for up to 18 months.

No additional burden for participants in this trial is expected.

Read the detailed description

The retrospective phase will be up to 2 years prior to enrollment to the study, the prospective phase will be up to 18 months after enrollment.

03

Conditions studied

  • Crohn's Disease

Browse trials for

Keywords

  • Crohn's Disease
  • Upadacitinib
  • Risankizumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult participants with Crohn's Disease

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with a diagnosis of moderate-to-severe Crohn's Disease (CD) confirmed by clinical, and/or endoscopic/histological indexes
  • Participants previously treated with Tumor Necrosis Factor inhibitor (TNF-i) as fist line (1L) therapy for at least 6 months; clinical documentation available in medical charts for the previous 2 years or since the beginning of the 1L therapy

Exclusion criteria

Exclusion Criteria:

  • Any condition included in the "warning and precautions" and "" section of the approved local upadacitinib/risankizumab label
  • Participants previously exposed to upadacitinib/risankizumab or any approved or non TNFi biologic Disease Modifying Antirheumatic Drug (bDMARDs) for CD
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
250 participants (estimated)

Groups and cohorts

  • Upadacitinib

    Participants with Crohn's Disease prescribed upadacitinib in routine clinical practice are observed from the first dose up to 18 months.

  • Risankizumab

    Participants with Crohn's Disease prescribed risankizumab in routine clinical practice are observed from the first dose up to 18 months.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants who Achieve Corticosteroids (CS) Free Remission

    CS free remission is defined as clinical remission with Harvey Bradshaw Index (HBI) \<4 and absence of corticosteroid use since at least three months prior to month 12.

    Time frame: Month 12

07

Study locations

25 of 25 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2027, 29 months after the start.

Of 73 industry-sponsored observational studies under Crohn Disease, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 60. This study's planned 29 months is below that.

Counting every sponsor, half of 305 studies reached it within 41 months; a quarter within 29 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2025
First posted
Jul 18, 2025
StartActual
Jul 14, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Jun 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07073079
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jul 18, 2025
Start date
Jul 14, 2025
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jun 24, 2026

Study contacts

Caterina Golotta
Contact
caterina.golotta@abbvie.com
+39 06 548891
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion